UNITED THERAPEUTICS COMPLETES ENROLLMENT FOR CANCER DRUG STUDY

United Therapeutics has completed enrollment in one of two Phase III clinical trials for Ovarex, the company's experimental drug for patients with late-stage ovarian cancer. The trial enrolled 177 people. The two upcoming Phase III trials will be conducted at more than 60 research centers in the U.S.

Ovarex is a monoclonal antibody for patients with Stage III/IV advanced ovarian cancer who are also being treated with chemotherapy. The investigational drug targets a protein expressed in most cases of ovarian cancer, and it is designed to help patients' immune systems recognize and more effectively fight the cancer.